Xanomeline clinical trials
Also written BMS-986519.
Counted the way a researcher would: Xanomeline with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses xanomeline is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the xanomeline studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 26 Sept 2024 · COBENFY · NDA 216158 (FDA, Drugs@FDA; in a combination)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- BMS-986519
- 9
Studies by the year they started
41 studies that test it; most in 2025 (16); 1 more planned to start later
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 3 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 16 |
| 2026 | 10 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 38 · Other 4
Bristol-Myers Squibb (18) · Karuna Therapeutics, Inc., a Bristol Myers Squibb company (15) · Karuna Therapeutics (5) · Vanguard Research Group (1) · Collaborative Neuroscience Research, LLC (1) · New York State Psychiatric Institute (1) · European Group for Research In Schizophrenia (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 11, 6 in phase 3
Studies that test xanomeline, phase 3 first.
- Nov 2026A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I DisorderPhase 3 · Bristol-Myers Squibb
- Nov 2026A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)Phase 3 · Bristol-Myers Squibb
- Nov 2026A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)Phase 3 · Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Dec 2026A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)Phase 3 · Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Jun 2027A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or LamotriginePhase 3 · Bristol-Myers Squibb
- Sep 2027Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)Phase 3 · Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Nov 2026Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy VolunteersPhase 4 · Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Dec 2026A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult ParticipantsPhase 1 · Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Mar 2027A Study to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC Reference Following Single Doses, Explore the Effect of Food After Multiple Doses of Selected Prototypes, and Evaluate Alternative Formulations of KarX and KarXT Following Single and Multiple Ascending DosesPhase 1 · Bristol-Myers Squibb
- Apr 2027A PET/MRI Study of Cobenfy on Dopamine Transmission in SchizophreniaPhase 1/2 · New York State Psychiatric Institute
Studies
Open first, then newest update. How each study uses xanomeline is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 42
- Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)RecruitingPhase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyNCT05980949Written as KarXT
- A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)RecruitingPhase 3Bristol-Myers SquibbNCT06937229Written as KarXT
- A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)RecruitingPhase 3Bristol-Myers SquibbNCT07288567Written as KarXT
- A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)RecruitingPhase 3Bristol-Myers SquibbNCT06951711Written as KarXT
- A Study to Evaluate the Effect of KarXT on Urological SafetyRecruitingPhase 4Bristol-Myers SquibbNCT07221877Written as Xanomeline/trospium chloride
- A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum DisorderRecruitingPhase 3Bristol-Myers SquibbNCT07285798Written as KarXT
- A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With AutismRecruitingPhase 3Bristol-Myers SquibbNCT07284745Written as KarXT
- A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)RecruitingPhase 3Bristol-Myers SquibbNCT07011732Written as Xanomeline/Trospium Chloride Capsule
- A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and AdolescentsRecruitingPhase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyNCT07424404Written as KarXT
- A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or LamotrigineRecruitingPhase 3Bristol-Myers SquibbNCT07140913Written as Xanomeline/Trospium Chloride
- A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's DiseaseRecruitingPhase 3Bristol-Myers SquibbNCT07011745Written as Xanomeline/Trospium Chloride Capsule
- A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With SchizophreniaRecruitingPhase 3Bristol-Myers SquibbNCT06882785Written as KarXT
- Relapse Prevention Trial Evaluating KarXT Treatment in SchizophreniaRecruitingPhase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyNCT07686263Written as Xanomeline/Trospium Chloride
- A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's DiseaseRecruitingPhase 3Bristol-Myers SquibbNCT06976216Written as KarXT
- A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)RecruitingPhase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyNCT06585787Written as KarXT
- A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)RecruitingPhase 3Bristol-Myers SquibbNCT06929273Written as KarXT
- A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I DisorderRecruitingPhase 3Bristol-Myers SquibbNCT06951698Written as KarXT
- A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)RecruitingPhase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyNCT06126224Written as KarXT
- Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy VolunteersRecruitingPhase 4Karuna Therapeutics, Inc., a Bristol Myers Squibb companyNCT07681076Written as KarXT
- A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult ParticipantsRecruitingPhase 1Karuna Therapeutics, Inc., a Bristol Myers Squibb companyNCT07204418Written as Xanomeline/ Trospium Chloride
See all 42 studies that test xanomeline →
Given beside what is tested · 3 — xanomeline is usual care or a partner of the new treatment
- A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and DigoxinCompletedPhase 1Karuna Therapeutics, Inc., a Bristol Myers Squibb companyNCT07118215Written as KarXT
- A Study to Evaluate the Effects of Lithium, Valproic Acid, and Lamotrigine on the Pharmacokinetics of KarXT and Effects of KarXT on the Pharmacokinetics of Lithium, Valproic Acid, and Lamotrigine in Healthy ParticipantsCompletedPhase 1Karuna Therapeutics, Inc., a Bristol Myers Squibb companyNCT06729970Written as Xanomeline/Trospium Chloride
- Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus TrospiumCompletedPhase 1Karuna TherapeuticsNCT02831231Written as xanomeline tartrate
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting2
Stopped1
Codes
What other systems call xanomeline · ClinicalTrials.gg INT003639
- MeSH (NLM) C075257xanomelineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 9ORI6L73CJXANOMELINEConfirmed FDA, NLM, Wikidata
- Wikidata Q8042940xanomelineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152926XanomelineOne source FDA
- DrugBank DB15357One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C075257 | xanomeline | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 9ORI6L73CJ | XANOMELINE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q8042940 | xanomeline | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152926 | Xanomeline | One source FDA |
| DrugBank | DB15357 | — | One source Wikidata |
Also registered as xanomeline tartrate (UNII B80W7AUT8R).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.